http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6191123-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d6256baf554e46784d8daa478a2ddc6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-38 |
| filingDate | 1984-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af9334a83d79250b2610712e2e4b8a58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64620767fb87b646acf6c5bf2b1c6aa7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41456e69750deffeb1b451760e1e19af |
| publicationDate | 1986-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S6191123-A |
| titleOfInvention | Novel antiulcer agent |
| abstract | PURPOSE: To provide an antiulcer agent containing 2-(1-piperazinyl)-4- phenylquinoline or its salt as an active component. n CONSTITUTION: An antiulcer agent can be prepared by using 2-(1-piperazinyl)-4- phenylquinoline or its salt (e.g. hydrochloride, hydrobromide, sulfate, citrate, etc.) as an active component. It can be administered orally or parenterally, preferably orally. Dose: 0.1W6mg/kg, preferably 0.2W2mg/kg daily. It is administered in the form of a solid preparation such as tablet, capsule, granule, powder, suppository, etc. or a liquid preparation such as syrup, elixir, injection, etc. The preparation may contain ≥0.5%, preferably 1W60% active component. n COPYRIGHT: (C)1986,JPO&Japio |
| priorityDate | 1984-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.